Dashboard
1
Poor Management Efficiency with a low ROCE of 18.72%
- The company has been able to generate a Return on Capital Employed (avg) of 18.72% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
Poor long term growth as Net Sales has grown by an annual rate of 313.74% and Operating profit at -322.52% over the last 5 years
4
Risky -
Stock DNA
Miscellaneous
CNY 28,779 Million (Large Cap)
NA (Loss Making)
NA
0.00%
-0.68
-55.70%
17.72
Revenue and Profits:
Net Sales:
195 Million
(Quarterly Results - Jun 2025)
Net Profit:
-185 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-19.31%
0%
-19.31%
6 Months
3.69%
0%
3.69%
1 Year
35.06%
0%
35.06%
2 Years
34.89%
0%
34.89%
3 Years
78.55%
0%
78.55%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Dizal (Jiangsu) Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
313.74%
EBIT Growth (5y)
-322.52%
EBIT to Interest (avg)
-7.00
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
27.08
Sales to Capital Employed (avg)
0.19
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
18.72%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
17.72
EV to EBIT
-30.04
EV to EBITDA
-32.72
EV to Capital Employed
52.74
EV to Sales
54.36
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-175.56%
ROE (Latest)
-55.70%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
194.60
121.40
60.30%
Operating Profit (PBDIT) excl Other Income
-175.80
-188.80
6.89%
Interest
8.70
5.20
67.31%
Exceptional Items
7.60
3.50
117.14%
Consolidate Net Profit
-185.30
-208.10
10.96%
Operating Profit Margin (Excl OI)
-999.00%
-1,715.20%
71.62%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 60.30% vs 0.00% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is 10.96% vs 24.24% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
357.90
90.40
295.91%
Operating Profit (PBDIT) excl Other Income
-896.80
-1,083.60
17.24%
Interest
22.80
7.60
200.00%
Exceptional Items
14.50
22.50
-35.56%
Consolidate Net Profit
-939.70
-1,107.70
15.17%
Operating Profit Margin (Excl OI)
-2,721.20%
-12,784.20%
1,006.30%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 295.91% vs 0.00% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 15.17% vs -50.50% in Dec 2023
About Dizal (Jiangsu) Pharmaceutical Co., Ltd. 
Dizal (Jiangsu) Pharmaceutical Co., Ltd.
Miscellaneous
No Details Available.
Company Coordinates 
No Company Details Available






